A study of a new drug compared to daratumumab
Treatments studied
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This study compares a new experimental drug called QL2109 with an approved treatment called daratumumab in healthy male volunteers. It is a first-in-human trial, which means the drug is being tested in people for the first time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be male and between 18 and 50 years old
- Weigh at least 55 kilograms (about 121 pounds) and have a body mass index (BMI) between 18 and 28
- Be in good general health with no significant medical conditions
- Agree to use reliable birth control during the study and for 6 months after
- Have no history of certain infections, allergies, or recent treatments like daratumumab
- Not have hepatitis B, hepatitis C, syphilis, or HIV
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing a new drug called QL2109 combined with Darzalex Faspro (daratumumab and hyaluronidase) for people with multiple myeloma that has returned or not responded to earlier treatments. The goal is to see if this combination can better control the cancer compared to standard options.
This trial tests a new injectable treatment for people with multiple myeloma that has come back or not responded to previous therapies. It aims to see if the drug is safe and effective.
This trial tests different dosing schedules of daratumumab to find a more cost-effective option for patients with multiple myeloma who have already had a stem cell transplant and achieved at least a partial response. It aims to see if a lower dose can work just as well.
This trial tests a new medicine (GR1803) against a standard combination treatment for people whose multiple myeloma has come back or stopped responding to prior therapies. It aims to see if the new drug works better.
This trial tests two different drug combinations for people newly diagnosed with multiple myeloma who are not getting a stem cell transplant right away. It compares one drug (elranatamab) to another (daratumumab), both given with a standard three-drug regimen called RVd Lite, to see which works better.
This trial tests a combination of two drugs, daratumumab and lenalidomide, for patients with multiple myeloma that has not responded to previous treatments. It aims to see if this regimen can help when other therapies have stopped working.
Hear when a new Multiple myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.